Abstract
The treatment of patients with pituitary carcinomas as well as pituitary tumors classified as aggressive represents a major challenge to current medicine, given that this group of neoplasms is more severe in its development than the benign adenomas that mostly affect the gland. It is known that these neoplasms have a lower degree of satisfactory response after the usual treatments with th…